‘Cell & Gene Therapy 2022-2032: Expert predictions for the decade ahead’ report
Stay ahead of the curve and create steadfast commercialization networks with expert industry predictions
The sheer novelty of the precision medicine industry combined with the rapid speed it’s growing makes understanding the minds of cell and gene frontrunners an almost impossible task.

That’s why we’ve compiled the thoughts of numerous industry experts that cover a variation of functions, so together we can ready the world for the future of CGT as a frontline therapy.
Market leading contributors include:
  • Lynelle Hoch, SVP Cell Therapy Franchise, BMS
  • Tom Klima, Chief Commercial Officer, bluebird bio
  • Warner Biddle, Global Head of Commercial, Kite Pharma
  • Heather McDonald, VP Global Market Access – Cell and Gene Therapies, Bayer
Don’t hesitate to reach out if you have any questions.
Kind regards,
Download your copy of the Reuters Events: Cell & Gene Therapy USA Predictions Report today
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: https://www.thomsonreuters.com/en/privacy-statement.html.
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.